Program 4th International Symposium
All times are in CEST. All recordings are available up to three months after the symposium.
Day 2, Monday, 28 June 2021
16:00-16:10
Opening (live)
16:10-17:00
SESSION I: TRANSLATIONAL BIOLOGY
Chairs: Ralf Küppers, Essen/DE; Megan Lim, Philadelphia PA/USA
16:10
Single cell RNA-sequencing of the Hodgkin lymphoma tumor microenvironment
Christian Steidl, Vancouver/CAN
16:30
Genetics of classic Hodgkin lymphoma
Enrico Tiacci, Perugia/IT
16:50
Q&A (live)
17:00
Break
17:05-17:45
TRANSLATIONAL BIOLOGY
Oral Abstract Presentation
17:05
Genomic Landscape of Reed-Sternberg Cells of Hodgkin Lymphoma from Children, Adolescents, and Young Adults
M. Roshal, J. Z. Xiang, S. Park, M. Oberley, E. Ruchdeschel, M. Lim, G. Wertheim, M. Barth, T. M. Horton, B. Bhinder, K. Wha Eng, F. He, W. Zhang, A. Tan, O. Elemento, L. Giulino-Roth
17:15
CRISPR/Cas9-mediated knockout reveals important role of CD30 in classical Hodgkin lymphoma cell lines
A. L. Weiß, A. Lollies, M. A. Weniger, R. Küppers
17:25
KIR B haplotype modulates susceptibility to cHL in an EBV dependent manner
P. Jiang, M. Stulp, B. Hepkema, I. Nolte, A. van den Berg, A. Diepstra
17:35
Q&A (live)
17:45
Break
18:00-18:55
SESSION II: IMMUNE CHECKPOINT INHIBITION
Chairs: Peter Cole, New Jersey/USA; Stefan Gattenlöhner, Gießen/DE
18:00
T cells in the Hodgkin lymphoma microenvironment: implications for immune checkpoint inhibition
Arjan Diepstra, Groningen/NL
18:20
Q&A (live)
18:30
Break
18:35-19:25
IMMUNE CHECKPOINT INHIBITION
Oral Abstract Presentation
18:35
Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma
J. Hochberg, J. Basso, L. Klejmont, A. Flower, K. Bortfeld, L. Harrison, Q. Shi, H. Islam, P. Gerard, S. Voss, M. Cairo
18:45
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
C. Mauz-Korholz, S. Daw, M. Mascarin, A. Fernandez-Teijeiro, K. Kelly, F. Keller, E. Kim, A. Nahar, P. Marinello, B. Hoppe, L. Giulino-Roth
18:55
Elucidating cell-cell interactions in pediatric and adolescent Hodgkin Lymphoma for targeted therapy by single cell RNA sequencing
J. K. de Kanter, A. M. Brandsma, T. Margaritis, A. Beishuizen, M. Scheijde-Vermeulen, R. van Boxtel, F. Meyer-Wentrup
19:05
A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents – Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331.
S. M. Castellino, S. K. Parsons, Q. Pei, K. McCarten, S. Kessel, A. Punnett, T. M. Horton, T. O. Henderson, D. Hodgson, H. Dave, A. – M. Charpentier, F. G. Keller, K. M. Kelly
19:15
Q&A (live)
Day 3, Tuesday, 29 June 2021
16:00-17:10
SESSION III: GLOBAL EXPERIENCES
Chairs: Mario de Paula, Barretos/BR; Leanne Super, Melbourne/AU
16:00
Evolution of CLEHOP as a Cooperative Group and its Experience with the Latin American LH Protocol
David Veron, Buenos Aires/BR
16:20
Hodgkin lymphoma: Trials and tribulations in a middle income country. The first inclusive prospective paediatric cancer study in South Africa
Jennifer Geel, Johannesburg/ZA
16:40
Q&A (live)
16:50
Interactive Case Presentation (live)
17:10
Break
17:15-17:55
GLOBAL EXPERIENCES
Oral Abstract Presentation
17:15
Epstein Barr Virus in children and adolescents with classical Hodgkin Lymphoma: analysis of a cohort of 299 patients
V. Pereira1, S. Boudjemaa2, C. Besson3, P. Simon1, T. Leblanc4, J. Landman-Parker5, 6
17:25
High response rate to combined chemotherapy avoiding radiotherapy in children and adolescents with classical Hodgkin lymphoma. Preliminary results of GALOP LH 2017 Protocol.
E. M. Alfaro, M. Schelotto, M. Guitter, C. Sanchez, L. Peruzzo, C. Pennella, M. S. Felice, A. Dabezies, L. Castillo, P. Zubizarreta
17:35
The GATLA (Argentinian Collaborative Group) experience through international cooperation in Pediatric Hodgkin Lymphoma (HL)
D. Veron, P. Streitenberger, D. Freigeiro, M. Castellanos, M. Metzger
17:45
Q&A (live)
17:55
Break
18:10-19:00
SESSION IV: INTERNATIONAL TRIAL WORKSHOP
Chairs: Mitchell Cairo, New York/USA; Dieter Körholz, Gießen/DE
18:10
Global nLPHL trial proposal
Michael Binkley, Stanford, CA/USA; Jamie Flerlage, Memphis, TN/USA
18:30
ARIA Guide: a Comprehensive tool for the management of Childhood Cancer
Nikhill Bhakta, Memphis TN/USA
18:50
Q&A (live)
19:00
Break
19:05
Günther Schellong Award Ceremony
19:05-20:00
Interactive Case Presentation, Meet the Experts
19:15
Content
Day 4, Wednesday, 30 June 2021
16:00-16:50
SESSION V: RELAPSE TREATMENTS
Chairs: Stephen Daw, London/UK; Kara Kelly, Buffalo, NY/USA
16:00
Precision Medicine for Hodgkin Lymphoma
Lisa Giuliano Roth, New York/USA
16:20
Risk and Response adapted salvage treatments inR/R Classical HL in children and young people – European guidelines
Stephen Daw, London/UK
16:40
Panel discussion (live)
Panel members: Stephen Daw, London/UK; Karin Dieckmann, Vienna/AT; Kara Kelly, Buffalo, NY/USA;
Thierry Leblanc, Paris/FR
16:50
Break
16:55
Interactive Case Presentation (live)
17:30-17:45
RELAPSE TREATMENTS
Oral Abstract Presentation
17:30
The addition of bendamustine to Brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single centre series
A. McMillan1, A. T. O’Neill1, W. Townsend1, J. Lambert1, A. Virchis1, R. Shah2, L. Menezes3, P. Humphries3, K. Von Both2, V. Grandage4, R. Hough4, B. Carpenter4, K. M. Ardeshna1, S. Daw4
17:40
Q&A (live)
17:45
Break
18:00-20:00
SESSION VI: CELLULAR THERAPIES
Chairs: Cathrine Bollard, Washington D.C./USA; Birgit Burkhardt, Münster/DE
18:00
T cell therapies to overcome the tumor microenvironment in HL
Cathrine Bollard, Washington D.C./USA
18:20
CD30 CAR T for HL and ALCL
Barbara Savoldo, Houston, TX/USA
18:40
Study on Immunodeficiencies & EBV-induced HL
Sylvain Latour, Paris/FR
19:00
Q&A (live)
19:10
Interactive Case Presentation, Meet the Experts (live)
19:15-20:15
Interactive Case Presentation, Meet the Experts
19:15
Content
Day 5, Thursday, 1 July 2021
16:00-17:15
SESSION VII: CONTEMPORARY RADIOTHERAPY
Chairs: Karin Dieckmann, Vienna/AT; Brad Hoppe, Jacksonville, FL/USA
16:00
Panel Case Discussion (Intermediate risk)
Emphasis on field design
Maurizio Mascarin, Aviano/IT (EuroNet)
David Hodgson, Toronto/CAN (COG)
Matthew Krasin, Memphis, TN/USA (St. Jude/Stanford/Havard)
Questions
Cardiac/breast toxicity
Louis (Sandy) Constine, Rochester/USA
17:00
Q&A
17:15
Break
17:20-17:50
CONTEMPORARY RADIOTHERAPY
Oral Abstract Presentation
17:20
Reduction in Cardiac Radiation Dose Among Children Receiving Mediastinal RT: Comparison of Involved-Site vs Involved-Field RT Delivered in Three Children’s Oncology Group Trials.
S. Bergeron Gravel1, M. Khandwala2, S. L. Wolden3, S. M. Castellino4, D. L. Friedman5, K. M. Kelly6, K. B. Roberts7, L. S. Constine8, C. L. Schwartz9, T. J. Fitzgerald10, B. S. Hoppe11, D. Hodgson12
17:30
Cost-effectiveness of proton therapy for young adults with mediastinal lymphoma: analysis of an institutional cohort
R. B. Mailhot Vega, S. Patel, J. E. Bates, J. Lynch, M. Bansal, W. Slayton, S. K. Parsons, B. S. Hoppe, N. P. Mendenhall
17:40
Q&A (live)
17:50
Break
18:05-19:20
SESSION VIII: SURVIVORSHIP AND AFTERCARE
Chairs: Melissa Hudson, Memphis, TN/USA; Hamish Wallace, Edinburgh/UK
18:05
Fertility preservation
Hamish Wallace, Edinburgh/UK
18:25
Late Health Outcomes after Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
Matthew Ehrhardt, Memphis, TN/USA
18:45
Q&A (live)
18:55
Interactive Case Presentation, Meet the Experts (live)
19:20
Break
19:25-20:05
SURVIVORSHIP AND AFTERCARE
Oral Abstract Presentation
19:25
Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children’s Oncology Group Study AHOD0031
L. Giulino-Roth, Q. Pei, A. Buxton, R. Bush, S. L. Wolden, L. S. Constine, K. M. Kelly, C. L. Schwartz, D. L. Friedman
19:35
Late effects after Hodgkin lymphoma in childhood and adolescence – results of the German Survivor Cohort after 22 years of follow-up
U. Hennewig, A. Schneider, S. Mann, D. Körholz, C. Mauz-Körholz
19:45
Hyperlipoproteinemia, insulin resistance and metabolic syndrome in long-term survivors of Hodgkin lymphoma during childhood and adolescence
M. Cepelova, J. Kruseova, A. Luks, V. Capek, P. Cepela, J. Potockova, P. Kraml
19:55
Q&A (live)
Day 6, Friday, 2 July 2021
16:00-16:55
SESSION IX: SEARCH FOR CAYAHL
Chairs: Jamie Flerlage, Memphis TN/USA; Dietrich Stoevesandt, Halle/DE
16:00
„E“ Lesions of Lung – Imaging Update
Kathleen McCarten, Providence, RI/USA
16:20
Imaging for Hodgkin Lymphoma
Henrique Lederman, Sao Paolo/BR
16:40
Q&A – Discussion on Future Plans (live)
16:55
Break
17:00-17:40
SEARCH FOR CAYAHL
Oral Abstract Presentation
17:00
Methodological comparison of volumetric analysis on FDG PET in pediatric Hodgkin Lymphoma assessed at different timing
E. Lopci1, C. Elia2, A. Piccardo3, A. Castello1, E. Borsatti5, P. Zucchetta6, A. Cistaro3, R. Burnelli4, M. Mascarin2
17:10
The impact of the Point-spread-function (PSF) reconstruction on the response assessment in the Interim-PET (iPET) in Hodgkin lymphoma (HL)
T. W. Georgi, L. Kurch, D. Hasenclever, D. Körholz, O. Sabri, R. Kluge, C. Mauz-Körholz
17:20
Impact of central review of imaging in an FDG-PET response adapted Pediatric Hodgkin lymphoma protocol
B. S. Hoppe, S. M. Castellino, S. Kessel, A. Alazraki, S. Voss, J. Mhlanga, H. Lai, E. Eutsler, F. G. Keller, K. M. Kelly, S. Cho, K. McCarten
17:30
Q&A (live)
17:40
Break
17:45-18:50
SESSION X: AYA SESSION incl. Oral Abstract Presentation
Chairs: David Hodgson, Toronto/CAN; Maurizio Mascarin, Aviano/IT
17:45
HL biology in adolscents and young adults
Anja Mottok, Ulm/DE
18:05
Simulation modelling to delineate long term patient outcome in AYA HL
Susan Parsons, Boston, MA/USA
18:25
Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children’s Oncology Group trials
J. M. Kahn, K. M. Kelly, Q. Pei, D. L. Friedman, F. G. Keller, S. Bhatia, T. O. Henderson, C. L. Schwartz, S. M. Castellino
18:35
Q&A (live)
18:50
Break
19:00-19:30
AWARD SESSIONS AND CLOSE OUT
19:00
Poster Award Session (live)
19:15
Conclusion of 4-ISCAYAHL (live)
Christine Mauz-Körholz, Gießen/DE; Monika Metzger, Memphis, TN/USA
Setting Goals for the Next Meeting
See you 2023 in Memphis/TN USA
available all days
Recorded Poster presentation
Prognostic Value of Interim and End of Treatment PET-CT Scan Results in Pediatric Hodgkin Lymphoma
M. Abdelhalim, O. Zahra, N. El-Deeb, S. Fadel
Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma
R. Shyam1, D. Kurtz2, S. Alig2, M. Jin2, M. Link1, L. Marks1, A. Alizadeh2
An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826.
S. M. Castellino, M. LeBlanc, A. Herrera, S. K. Parsons, A. Punnett, D. Hodgson, S. Rutherford, N. Kahn, L. S. Constine, K. Davison, A. Prica, J. Friedberg, K. M. Kelly
Cardiac substructures dose sparing in pediatric Hodgkin’s lymphoma
I. Iamundo De Cumis, I. Solla, M. A. Deidda, R. Mura, R. Farigu, M. Mascarin, R. Barbara
3′ untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin’s lymphoma in Brazilian children and adolescents
B. O. Silva, A. N. Correia, T. F. Barros, L. P. O. Lima, A. L. Morais, R. Hassan, E. Dellalibera, M. D. S. M. Cavalcanti, M. T. C. Muniz
Assessment of tumor antigen specific T cell immunity and cytokine milieu at diagnosis in patients with high risk Hodgkin Lymphoma treated on Children’s Oncology Group trial AHOD1331
H. Dave, T. M. Horton, M. Mai, D. Saunders, G. Jenkins, Q. Pei, F. G. Keller, S. M. Castellino, K. M. Kelly, C. Bollard
Comparative proteomic profiling in recurrent pediatric/adolescent Hodgkin Lymphoma
O. Repetto, L. Mussolin, C. Elia, L. Caggiari, M. De Zorzi, A. Garbin, C. Diamanti, I. Gallingani, M. Bianchi, S. Buffardi, A. Sala, R. Burnelli, E. Facchini, M. Mascarin, V. De Re
Nodular Lymphocyte Predominant Hodgkin Lymphoma – experience of Polish Pediatric Leukemia/Lymphoma Study Group
T. Klekawka, A. Moryl-Bujakowska, K. Smalisz, A. Brozyna, J. Kwasnicka, R. Chaber, I. Ruranska, A. Wziatek, M. Mitura-Lesiuk, T. Stachowicz-Stencel, A. Koltan, K. Muszynska-Roslan, M. Stolarska, A. Mizia-Malarz, M. Woszczyk, A. Urbanek-Dadela, B. Przybyszewski, K. Zielezinska, W. Balwierz
Real-life experience of multisciplinary pediatric lymphoma tumor board: decision’s impact on Hodgkin Lymphoma treatment choice and results
A. Potier, F. Montravers, H. Ducou Le Pointe, T. Leblanc, H. Pacquement, L. Brugieres, C. Rigaud, M. – E. Dourthe, P. Brice, V. Martin, S. Boudjemaa, S. Helfre, J. Landman-Parker
Result of therapy for Hodgkin Lymphoma (HL): a report from the Chilean pediatric National Cancer Program (PINDA)
E. Concha, M. Cordova, A. Becker, C. Rizzardini, C. Salgado, V. Perez, E. Fernandez, F. Espinoza, P. Martinez, M. Valero, L. Neira, M. Arriagada
Expression of human endogenous retroviruses and associated transcripts in Hodgkin lymphoma cells
K. Engel, A. Krüger, V. Vandrey, J. Schneider, I. Volkmer, A. Emmer, M. S. Staege
BV-DHAP as salvage treatment for high risk adolescent Hodgkin lymphoma
P. Muggeo, R. Angarano, R. M. Daniele, G. Ingravallo, N. Santoro
Brentuximab vedotin (BV) in recurrent and refractory Hodgkin Lymphoma (HL) in children. Experience of Polish Pediatric Leukemia/Lymphoma Study Group
T. Klekawka, A. Moryl-Bujakowska, K. Smalisz, J. Kwasnicka, R. Chaber, A. Wziatek, T. Stachowicz-Stencel, A. Brozyna, A. Koltan, M. Stolarska, B. Przybyszewski, K. Zielezinska, W. Balwierz
Pediatric lymphocyte-predominant Hodgkin lymphoma: Review of Spanish patients between November-2007 and October-2019
A. I. Carboné, M. Garcia, C. Bárcena, M. Guibelalde, J. L. Vivanco, C. Garrido, A. Echebarria, M. Coronado, A. Fernández-Teijeiro
Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma
Y. Koga, M. Sekimizu, A. Iguchi, A. Kada, A. Sait, R. Asada, T. Mori, K. Horibe
A specific chromatin structure and increased RUNX3 expression contribute to the Hodgkin/Reed-Sternberg cell-specific phenotype
T. Jox, T. Zimmermann, M. Bartkuhn, A. Bräuninger, S. Gattenlöhner, D. Körholz
Hyperthyroidism as late adverse effect of treatment for Hodgkin lymphoma
D. Hori, R. Kobayashi, S. Matsushima, M. Yanagi, K. Kodama, D. Suzuki, K. Kobayashi
Anemia: frequency and type in pediatric patients with Hodgkin’s lymphoma
M. L. Oscanoa Gutierrez, C. Rivera, A. Yabar
Prognostic model for pediatric Hodgkin Lymphoma patients in developing country
E. F. de Azevedo, T. B. S. Tenório, R. S. Almeida, G. T. N. Diniz, F. Pedrosa, N. Lucena-Silva
Outcome of Pediatric Relapsed/Refractory Hodgkin Lymphoma Patients in 2 different Latin American Settings: AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) and GATLA (Grupo Argentino de Tratamiento de Leucemia Aguda)
D. Veron, P. Streitenberger, M. Castellanos, J. Blanco, P. de Alarcon, M. Metzger
Is it Possible to Work together in Latin America? The Latin American Consortium (CLEHOP) experience with Hodgkin Lymphoma (HL)Outcome of Pediatric Relapsed/Refractory Hodgkin Lymphoma Patients in 2 different Latin American Settings: AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) and GATLA (Grupo Argentino de Tratamiento de Leucemia Aguda)
D. Veron, M. Castellanos, A. Arancibia, M. de Paula, P. de Alarcon, M. Metzger
Better outcome of children with newly-diagnosed classical Hodgkin’s lymphoma treated with PET response-guided treatment in Taiwan: A single center experience
S. – H. Chen, C. Lin, C. – P. Yang, T. – H. Jaing, C. – K. Tseng, T. – Y. Chang, W. – H. Kao, C. Hsueh, I. – J. Hung
Expression of splice variants of the transcription factor ONECUT2 in Hodgkin lymphoma cells
P. Lein, I. Volkmer, M. S. Staege
Outcomes after initial refusal of curative treatment in patients with Hodgkin lymphoma in British Columbia
M. Chahal, A. Jiang, A. Hayden, K. Savage, D. Villa, D. Scott, A. Gerrie, A. Lo, M. Chan, T. Pickles, J. Connors, L. Sehn, C. Freeman
CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
J. Veldman, J. Rodrigues Plaça, L. Chong, M. M. Terpstra, M. Mastik, L. van Kempen, T. Aoki, C. Steidl, A. van den Berg, L. Visser, A. Diepstra
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
E. A. M. Zijtregtop, W. – C. Wong, R. Hoogendijk, A. Thano, C. M. Zwaan, F. Meyer-Wentrup, A. Beishuizen
Clinical trial of Pediatric Hodgkin Lymphoma in Japan and Next Trial Plan
M. Kamei, Y. Koga, R. Fukano, K. Oki, T. Mori, A. Nakazawa, M. Tanaka, T. Tsuchimochi, D. Hori, N. Fujita, T. Mitui, T. Mori, R. Kobayashi
Immunologic dysfunction and Hodgkin Lymphoma: two sides of a coin?
R. Rana, P. Muggeo, R. M. Daniele, G. Arcamone, M. Grassi, R. Angarano, N. Santoro
Long-term-survival of pediatric Hodgkin lymphoma (HL) patients after GPOH-HD 2002 study treatment
K. A. Rozwod, U. Hennewig, A. Schneider, A. Ismail, S. Avondstondt, D. Körholz, C. Mauz-Körholz